Feasibility and acceptability of targeted screening for congenital CMV-related hearing loss

Williams, Eleri J., Kadambari, Seilesh, Berrington, Janet E., Luck, Suzanne, Atkinson, Claire, Walter, Simone, Embleton, Nicholas D., James, Peter, Griffiths, Paul, Davis, Adrian, Sharland, Mike and Clark, Julia E. (2014) Feasibility and acceptability of targeted screening for congenital CMV-related hearing loss. Archives of Disease in Childhood: Fetal and Neonatal Edition, 99 3: F230-F236. doi:10.1136/archdischild-2013-305276

Author Williams, Eleri J.
Kadambari, Seilesh
Berrington, Janet E.
Luck, Suzanne
Atkinson, Claire
Walter, Simone
Embleton, Nicholas D.
James, Peter
Griffiths, Paul
Davis, Adrian
Sharland, Mike
Clark, Julia E.
Title Feasibility and acceptability of targeted screening for congenital CMV-related hearing loss
Journal name Archives of Disease in Childhood: Fetal and Neonatal Edition   Check publisher's open access policy
ISSN 1468-2052
Publication date 2014
Sub-type Article (original research)
DOI 10.1136/archdischild-2013-305276
Open Access Status Not Open Access
Volume 99
Issue 3
Start page F230
End page F236
Total pages 7
Place of publication London, United Kingdom
Publisher BMJ Publishing Group
Language eng
Formatted abstract
Background Congenital cytomegalovirus (cCMV) is the most common non-genetic cause of sensorineural hearing loss (SNHL) in children. Ganciclovir has been shown to prevent the continued deterioration in hearing of children with symptomatic cCMV, but some children with cCMV-related SNHL are unidentified in the neonatal treatment period. Neonatal cCMV screening provides an opportunity to identify infants with cCMV-related SNHL who might benefit from early treatment.

Objectives To assess the feasibility (ability to take samples before 3 weeks of age and clinical assessment by 30 days of age) and acceptability (maternal anxiety) of targeted CMV testing of infants who are ‘referred’ for further audiological testing after routine newborn hearing screening programme (NHSP).

Methods Parents of infants who have ‘no clear responses’ on routine NHSP before 22 days of life in London and North East England were approached. Salivary and urine samples were tested by CMV PCR. At recruitment and 3 months, the short form Spielberger State-Trait Anxiety Inventory measured maternal anxiety.

Results 411 infants were recruited. 99% (407/411) returned a sample; 98% (404/411) successfully yielded a CMV result, 6 had cCMV, all diagnosed on salivary samples taken <22 days of age (1.5%; 95% CI 0.6% to 3.2%). Only 50% returned urine samples compared with 99% returning salivary samples (p<0.001). Using saliva swabs 98% were successfully screened for CMV within 3 weeks. All positive screening CMV results were known by day 23, and 5/6 infants with cCMV were assessed within 31 days. Anxiety was not increased in mothers of infants screened for cCMV.

Conclusions Targeted salivary screening for cCMV within the NHSP is feasible, acceptable and detects infants with cCMV-related SNHL who could benefit from early treatment.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 13 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 11 Dec 2015, 19:20:36 EST by System User on behalf of School of Medicine